Francesca Romana Ponziani

Prof. Dr. Francesca Romana Ponziani

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
SBSherrie Bhoori
Sherrie Bhoori
CCChiara Castelli
Chiara Castelli
LPLorenza Putignani
Lorenza Putignani
LRLicia Rivoltini
Licia Rivoltini
VMVincenzo Mazzaferro
Vincenzo Mazzaferro

NTNatalia Di Tommaso
Natalia Di Tommaso
Antonio GasbarriniAntonio Gasbarrini
Antonio Gasbarrini
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
The intestinal mucosa provides a selective permeable barrier for nutrient absorption and protection from external factors. It consists of epithelial cells, immune cells and their secretions. The gut microbiota participates in regulating the integrity and function of the intestinal barrier in a homeostatic balance. Pathogens, xenobiotics and food can disrupt the intestinal barrier, promoting systemic inflammation and tissue damage. Genetic and immune factors predispose individuals to gut barrier dysfunction, and changes in the composition and function of the gut microbiota are central to this process. The progressive identification of these changes has led to the development of the concept of ‘leaky gut syndrome’ and ‘gut dysbiosis’, which underlie the relationship between intestinal barrier impairment, metabolic diseases and autoimmunity. Understanding the mechanisms underlying this process is an intriguing subject of research for the diagnosis and treatment of various intestinal and extraintestinal diseases.

1 October 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
MZMaria Assunta Zocco
Maria Assunta Zocco
ESEnrico Di Stasio
Enrico Di Stasio
RCRaimondo De Cristofaro
Raimondo De Cristofaro
MNMarialuisa Novi
Marialuisa Novi
MAMaria Elena Ainora
Maria Elena Ainora
AGAntonio Gasbarrini
Antonio Gasbarrini

1 January 2010 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
MZMaria A Zocco
Maria A Zocco
CCChiara Campanale
Chiara Campanale
Rinninella EmanueleRinninella Emanuele
Rinninella Emanuele
ATAnnalisa Tortora
Annalisa Tortora
AGAntonio Gasbarrini
Antonio Gasbarrini
Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment

Verified
Journal Article
Open access
PDF file
ANAntonio Nesci
Antonio Nesci
CCClaudia Carnuccio
Claudia Carnuccio
VRVittorio Ruggieri
Vittorio Ruggieri
ADAlessia D’alessandro
Alessia D’alessandro
AGAngela Di Giorgio
Angela Di Giorgio
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
Several studies in recent years have demonstrated that gut microbiota–host interactions play an important role in human health and disease, including inflammatory and cardiovascular diseases. Dysbiosis has been linked to not only well-known inflammatory diseases, such as inflammatory bowel diseases, rheumatoid arthritis, and systemic lupus erythematous, but also to cardiovascular risk factors, such as atherosclerosis, hypertension, heart failure, chronic kidney disease, obesity, and type 2 diabetes mellitus. The ways the microbiota is involved in modulating cardiovascular risk are multiple and not only related to inflammatory mechanisms. Indeed, human and the gut microbiome cooperate as a metabolically active superorganism, and this affects host physiology through metabolic pathways. In turn, congestion of the splanchnic circulation associated with heart failure, edema of the intestinal wall, and altered function and permeability of the intestinal barrier result in the translocation of bacteria and their products into the systemic circulation, further enhancing the pro-inflammatory conditions underlying cardiovascular disorders. The aim of the present review is to describe the complex interplay between gut microbiota, its metabolites, and the development and evolution of cardiovascular diseases. We also discuss the possible interventions intended to modulate the gut microbiota to reduce cardiovascular risk.

26 December 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
Anna PiccaAnna Picca
Anna Picca
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
Riccardo CalvaniRiccardo Calvani
Riccardo Calvani
Federico MariniFederico Marini
Federico Marini
Alessandra BiancolilloAlessandra Biancolillo
Alessandra Biancolillo
Emanuele MarzettiEmanuele Marzetti
Emanuele Marzetti
Physical frailty and sarcopenia (PF&S) share multisystem derangements, including variations in circulating amino acids and chronic low-grade inflammation. Gut microbiota balances inflammatory responses in several conditions and according to nutritional status. Therefore, an altered gut-muscle crosstalk has been hypothesized in PF&S. We analyzed the gut microbial taxa, systemic inflammation, and metabolic characteristics of older adults with and without PF&S. An innovative multi-marker analytical approach was applied to explore the classification performance of potential biomarkers for PF&S. Thirty-five community dwellers aged 70+, 18 with PF&S, and 17 nonPF&S controls were enrolled. Sequential and Orthogonalized Covariance Selection (SO-CovSel), a multi-platform regression method developed to handle highly correlated variables, was applied. The SO-CovSel model with the best prediction ability using the smallest number of variables was built using seven mediators. The model correctly classified 91.7% participants with PF&S and 87.5% nonPF&S controls. Compared with the latter group, PF&S participants showed higher serum concentrations of aspartic acid, lower circulating levels of concentrations of threonine and macrophage inflammatory protein 1α, increased abundance of Oscillospira and Ruminococcus microbial taxa, and decreased abundance of Barnesiellaceae and Christensenellaceae. Future investigations are warranted to determine whether these biomediators are involved in PF&S pathophysiology and may, therefore, provide new targets for interventions.